Aug 19, 2025 • Benzinga
SOMEWHAT-BULLISH
Insider Decision: Frederick Hudson Offloads $315K Worth Of Supernus Pharmaceuticals Stock - Supernus Pharmaceuticals ( NASDAQ:SUPN )
Making a noteworthy insider sell on August 18, Frederick Hudson, Director at Supernus Pharmaceuticals SUPN, is reported in the latest SEC filing. What Happened: Hudson's decision to sell 7,457 shares of Supernus Pharmaceuticals was revealed in a Form 4 filing with the U.S.
Aug 05, 2025 • Zacks Commentary
NEUTRAL
Supernus Pharmaceuticals ( SUPN ) Surpasses Q2 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +93.62% and +7.34%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 01, 2025 • Motley Fool
NEUTRAL
Sage ( SAGE ) Q2 Revenue Jumps 264%
Sage Therapeutics ( NASDAQ:SAGE ) , a biopharmaceutical company focused on developing medicines for brain health disorders, released its second quarter 2025 results on July 30, 2025. The most important news from the quarter was the significant revenue beat, as sales reached $31.7 million ( GAAP ) ...
Jul 31, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.
Jul 31, 2025 • Benzinga
SOMEWHAT-BULLISH
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - Supernus Pharmaceuticals ( NASDAQ:SUPN ) , Sage Therapeutics ( NASDAQ:SAGE )
ROCKVILLE, Md., July 31, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. SUPN ( "Supernus" ) today announced that it has successfully completed its previously announced acquisition of Sage Therapeutics, Inc. SAGE ( "Sage" ) .
Jul 31, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Acquisition strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® ( zuranolone ) , and a novel CNS discovery platform, accelerating mid- to long-term revenue and cash flow growth and further diversifying revenue base Acquisition ...